Landos Biopharma's Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021

Omilancor shows efficacy and tolerability as a potential once-daily, oral, gut-restricted therapy for mild-to-moderate UC patients Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated clinical trial site feasibility stud